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Abstract
A strain of Klebsiella pneumoniae (K1) was isolated from a catheterized patient with a urinary tract infection. The patient was subse-
quently treated with meropenem, after which K. pneumoniae (K2) was once again isolated from the patient’s urine. Susceptibility testing
showed that strain K1 was fully susceptible to carbapenem antibiotics with the exception of ertapenem, to which it exhibited intermedi-
ate resistance, whilst K2 was resistant to ertapenem and meropenem. From pulsed-ﬁeld gel electrophoresis proﬁling both strains exhib-
ited identical banding patterns. Both contained CTX-M-15, OXA-1, SHV-1 and TEM-1 b-lactamase genes following PCR analyses. Outer
membrane protein analysis demonstrated that K1 and K2 lacked an OMP of c. 40 kDa, with an additional OMP of c. 36 kDa missing
from K2. Mutation studies showed that the K2 OMP phenotype could be selected by single-step carbapenem-resistant mutants of K1.
Expression of transcriptional activator ramA and efﬂux pump component gene acrA were up-regulated in both strains by RT-PCR. Nei-
ther strain expressed ompK35, but ompK36 was found in both. Sequence analysis revealed gene sequences of ompK35, ompK36 and
ramR in both strains; notably, ramR contained a mutation resulting in a premature stop codon. Transconjugation studies demonstrated
transfer of a plasmid into E. coli encoding the CTX-M-15, TEM-1 and OXA-1 b-lactamases. We concluded that the carbapenem-resistant
phenotype observed from this patient was attributable to a combination of CTX-M-15 b-lactamase, up-regulated efﬂux and altered
outer membrane permeability, and that K2 arose from K1 as a direct result of meropenem therapy.
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Introduction
Over the last three decades an increasing number of antibi-
otic resistance mechanisms have been emerging in members
of the Enterobacteriaceae, particularly to the b-lactam antibi-
otics [1,2]. Resistance to these agents is most commonly
mediated by either the production of enzymes, b-lactamases,
which act to hydrolyse and therefore disable the antibio-
tics, or by the alteration of the expression of the outer
membrane proteins (OMPs), which can act to decrease the
diffusion of antibiotics through the cell membrane, preventing
access to their target site [3,4]. Often a combination of both
can result in extremely high levels of resistance to most, if
not all, b-lactam antibiotics [3]. The loss of expression of
two of the major OMPs in K. pneumoniae, OmpK35 and
OmpK36, has been shown to contribute signiﬁcantly to
reduced susceptibility to b-lactam antibiotics in several stud-
ies [4,5]. Studies suggest that such porin loss coupled with
extended-spectrum b-lactamase (ESBL) production can con-
fer resistance to b-lactam antibiotics, including carbapenems
[5,6].
It has previously been shown that reduced susceptibility
to both ertapenem and meropenem can be achieved via the
overexpression of efﬂux genes, in particular, members of the
resistance-nodulation division (RND) family; however, imipe-
nem susceptibility remains unchanged, suggesting that it is
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE BACTERIOLOGY
not a good substrate for these efﬂux systems [7–9]. RND
family efﬂux pumps have been shown to have a broad sub-
strate range, demonstrating that the activation of a single
resistance mechanism can result in clinical levels of resistance
to several classes of antibiotics [10]. Overexpression of
efﬂux pumps has been shown to contribute to carbapenem
resistance in Pseudomonas aeruginosa, usually in conjunction
with porin loss and/or ampC overexpression [7,11].
Klebsiella pneumoniae is known to cause a variety of seri-
ous nosocomial infections, particularly in immunocomprom-
ized patients. In recent years, the incidence of carbapenem
resistance in K. pneumoniae has increased signiﬁcantly, largely
due to the production and dissemination of carbapenemases
such as the KPC enzymes [12]. A study by the National
Healthcare Safety Network in the USA over a 12-month per-
iod from 2006 to 2007 revealed that K. pneumoniae com-
prised 5.8% of the total hospital-acquired infections (HAIs)
and 7.7% of catheter-associated urinary tract infections
(UTIs) [13]. The same study showed that 21.2% of those
K. pneumoniae isolates were resistant to cephalosporins and
10.1% exhibited resistance to carbapenems [13]. These drugs
are traditionally viewed as the ‘drugs of last resort’ for multi-
drug-resistant (MDR) K. pneumoniae infections.
In this report we describe the in vivo clinical development
of carbapenem resistance in a strain of K. pneumoniae after
meropenem therapy.
Materials and Methods
Bacterial strains
K. pneumoniae strains K1 and K2 were found in separate
urine samples from a catheterized patient with a UTI, in
Hairmyres Hospital, Scotland, in 2008. K1 was collected
prior to meropenem therapy and K2 was collected after me-
ropenem therapy 5 days later. Carbapenem-susceptible
K. pneumoniae ATCC 13883 was used as a control strain for
OMP proﬁling and susceptibility testing. K. pneumoniae
MGH78578, a clinical strain that contains the b-lactamases
TEM-1 and SHV-12 and does not produce the OMP
OmpK35 [14,15], was used as a control strain in mutation
studies. Two previously characterized CTX-M-15 b-lactam-
ase-containing K. pneumoniae strains, CTX-M-15 (1) and
CTX-M-15 (2) (46th Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy, abstract no. 86),
were included as controls for susceptibility disc testing. A
KPC-2-containing K. pneumoniae was used as a control for
the modiﬁed Hodge test and Escherichia coli 25922 was used
as the indicator strain. Rifampicin-resistant E. coli J62-2 was
used as a recipient strain in transconjugation studies.
Susceptibility testing
Susceptibility testing was performed by agar doubling dilution
according to British Society for Antimicrobial Chemotherapy
(BSAC) guidelines [16]. MICs were determined to the following
antibiotics: amikacin, ampicillin, aztreonam, cefoxitin, ceftazi-
dime, chloramphenicol, ciproﬂoxacin, colistin, ertapenem,
gentamicin, imipenem, imipenem/EDTA, meropenem, piperacil-
lin, sulbactam, tetracycline, tigecycline and tobramycin. Clavul-
anic acid synergy testing was performed with clavulanic acid
incorporated into Iso-sensitest (IST) agar (Oxoid, Hampshire,
UK) at 4 mg/L and using 10 lg ertapenem discs (Oxoid).
Pulsed-ﬁeld gel electrophoresis (PFGE) typing
PFGE was performed according to the protocol of Miranda
et al. [17]. Plugs were digested with XbaI. PFGE was per-
formed with a CHEF-DRII system (Bio-Rad, Hertfordshire,
UK) with a pulse time of 5–40 s over 22 h at 200 V. A Lambda
Ladder PFG Marker (New England Biolabs, Hertfordshire,
UK) was used as a size standard.
PCR detection of b-lactamase genes
Isolates K1 and K2 were screened by PCR for the presence
of the genes for the following b-lactamases: AmpC, CTX-M,
GES, GIM, IMP, KPC, NDM, NMC/IMI, OXA, PER, SHV, SIM,
SME, SPM, TEM, VEB and VIM. Positive control clinically-
isolated strains were used for each PCR. Ampliﬁcation was
carried out using cell lysate with Promega Go-Taq polymerase
(Promega, Hampshire, UK) and all products were sequenced.
All primers used in this study are listed in Table 1.
Modiﬁed Hodge test
A modiﬁed Hodge test was performed to detect carbape-
nemase activity in strains K1 and K2 [18].
Analysis of gene expression
Total RNA was extracted from isolate cultures in the expo-
nential growth phase (OD  0.5) using the RiboPure Bacteria
kit (Ambion, Warrington, UK) and treated with DNase 1.
cDNA was synthesized from 120 ng of RNA using the Proto-
Script M-MuLV First Strand cDNA Synthesis kit (New England
Biolabs). One microlitre of cDNA was used in PCR reactions.
PCR reactions were run on an agarose gel and stained with
ethidium bromide for visualization. All assays were performed
in duplicate and with genomic DNA controls.
Outer membrane proﬁling
Outer membrane proteins were extracted according to the
protocol of Tsu-Lan et al. [23]. Cultures were grown in both
high osmolarity medium (LB broth) and low osmolarity med-
ium (NB broth) as OmpK35 expression is known to be
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inhibited in the former [24]. Protein concentrations were
estimated using a Nanodrop 1000 spectrophotometer and c.
50 lg was separated on a 12% SDS PAGE gel. Gels were
stained with coomassie blue.
Mutation studies
Overnight broth cultures of K1 and MGH78578 were spread
onto IST agar plates containing either ertapenem or merope-
nem at 4–16· their respective MICs. Plates were incubated
for 24 h and colonies were picked for further analysis of
their susceptibility and OMP proﬁles.
Sequencing of ompK35, ompK36 and ramR
OMP genes ompK35 and ompK36 and ramR were ampliﬁed
and sequenced from strains K1, K2 and ATCC 13883. OMP
gene sequences of ATCC 13883 and the ramR gene
sequence from the sequenced genome of K. pneumoniae
MGH78578 (NC 009648) were used as comparators.
Plasmid proﬁling
The plasmids of K1 and K2 were proﬁled using the S1 nucle-
ase/PFGE method [25]. Brieﬂy, agarose plugs of K1 and K2
were digested at 37C for 45 min with 8 U of S1 nuclease.
Reactions were stopped with the addition of 0.5 M EDTA
and plugs were run by PFGE under the same conditions as
used for XbaI typing.
Transconjugation studies
Transconjugation assays were performed as follows: over-
night cultures of the recipient (E. coli J62-2) and donor
strains (K1 and K2) were mixed in a 1:4 ratio, and cells were
collected by centrifugation and resuspended in 30 lL of cold
saline. Five microlitre aliquots of the resuspension were
spotted onto a nutrient agar plate and incubated at 37C for
6 h. Growth was collected and resuspended in cold saline
and inoculated onto nutrient agar plates containing rifampicin
at 16 mg/L and one of the selective antibiotics, gentamicin,
ceftazidime or meropenem, at a range of concentrations.
Results
Susceptibility proﬁles
Both strains K1 and K2 were resistant to most antibiotics
tested, with the following exception: K2 was resistant to
both ertapenem and meropenem, with intermediate resis-
tance to imipenem, whilst K1 was susceptible to all three
(Table 2). Colistin was the only antibiotic to which both
strains were susceptible. Antibiotic disc testing in the pres-
ence of clavulanic acid showed that ertapenem disc diame-
ters increased signiﬁcantly in the presence of clavulanic acid
for strains K1, K2, CTX-M-15 (1) and CTX-M-15 (2) but no
change was observed for ATCC 13883 or MGH78578
(Table 3).
PFGE analysis
Strains K1 and K2 showed identical banding patterns by
PFGE analysis, indicating that they are of the same clonal
type (Fig. 1). This suggests that K1 and K2 are almost cer-
tainly isogenic, K1 being the progenitor of K2.
TABLE 1. The primers used in this study
Primers Forward sequence (5¢–3¢) Reverse sequence (5¢–3¢) Product size (bp) References
Gene detection and sequencing
AmpC_F & R ATCAAAACTGGCAGCCG GAGCCCGTTTTATGCACCCA 550 [6]
CTX_F & R GACGTCCGTATTTGCCTTC ACCGTCGGTGACGATTTTAG 985 [19]
GES_F & R ATGCGCTTCATTGACGCAC CTATTTGTCCGTGCTCAGG 864 [20]
GIM_F & R TCGACACACCTTGGTCTGAA AACTTCCAACTTTGCCATGC 477 [21]
IMP_F & R GGAATAGAGTGGCTTAAYTCTC CCAAACYACTASGTTATCT 188 [21]
KPC_F & R CAGCTCATTCAAGGGCTTTC GGCGGCGTTATCACTGTATT 196 This work
NDM_F & R GACCGATGACCGCCCAG GACTTGGCCTTGCTGTCCTT 372 This work
NMC/IMI_F & R ATGTCATTAGGTGATATGGC GCATAATCATTTGCCGTACC 398 [6]
OXA_F & R CCGTTAAAATTAAGCCCTTT GGTCTGTGACTTTGCCGTCT 994 This work
PER_F & R ATGAATGTCATTATAAAAGC AATTTGGGCTTAGGGCAGAA 925 [20]
SHV_F & R CGCCGGGTTATTCTTATTTG CCACGTTTATGGCGTTACCT 1069 This work
SIM_F & R TACAAGGGATTCGGCATCG TAATGGCCTGTTCCCATGTG 570 [21]
SME_F & R TAGAGGAAGACTTTGATGGG GCATAATCATTCGCAGTACC 636 [6]
SPM_F & R AAAATCTGGGTACGCAAACG ACATTATCCGCTGGAACAGG 271 [21]
TEM_F & R AGACGTCAGGTGGCACTTTT GGCACCTATCTCAGCGATCT 977 [22]
VEB_F & R CGACTTCCATTTCCCGATGC GGACTCTGCAACAAATACGC 643 [20]
VIM_F & R GATGGTGTTTGGTCGCATA CGAATGCGCAGCACCAG 390 [21]
OmpK35_F & R ATTTTGCACAAAAGGGGATG AGAATTGGTAAACGATACCCACG 1117 This work & [6]
OmpK36_F & R CAGCACAATGAATATAGCCGAC GCTGTTGTCGTCCAGCAGGTTG 1126 [6]
RamR_F & R CATCCCGGAGGCTTTATGAT CGCTCGACCTTAAACACGTC 862 This work
RT-PCR analysis
ramA_RTF & RTR CTGCAACGGCTGTTTTTACA GTGGTTCTCTTTGCGGTAGG 334 This work
acrA_RTF & RTR GTCCTCAGGTCAGTGGCATT GGTGCCCAACAGTTTCTGAT 200 This work
ompK35_RTF & RTR AAAACGGCAACAAACTGGAC AGACGGGTTTTTGTGGTCTG 211 This work
ompK36_RTF & RTR GCGCTCTGTCTCCTACCAAC GGTGTACTGAGTGGCCAGGT 188 This work
16S_RTF & RTR CAGCCACACTGGAACTGAGA GTTAGCCGGTGCTTCTTCTG 220 This work
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b-Lactamase detection
Both strains were shown to contain the b-lactamases CTX-
M-15, OXA-1, TEM-1 and SHV-1, but no carbapenemases
were detected. The modiﬁed Hodge test showed no indica-
tion of carbapenemase activity.
OMP analysis and sequencing
OMP analysis showed that both K1 and K2 lacked a major
OMP of around 40 kDa, assumed to be OmpK35, when
compared with the proﬁle of ATCC 13883. K2 was also
shown to lack another protein of around 36 kDa, compatible
with OmpK36 (Fig. 2). The sequencing of ompK35 and
ompK36 from K1, K2 and ATCC 13883 revealed a number
of mutations in both genes when compared with ATCC
13883 but identical sequences between the two strains.
Therefore the 36 kDa protein found lacking in K2 cannot be
TABLE 2. The susceptibility proﬁles of K1, K2, the K1 meropenem mutant, the K1 ertapenem mutant, MGH78578 and the
MGH78578 meropenem mutant
Antibiotic K1 S/I/R K2 S/I/R K1_Mero S/I/R K1_Ert S/I/R MGH S/I/R MGH_Mero S/I/R
Amikacin 32 R 32 R 32 R 32 R 2 S 2 S
Ampicillin >512 R >512 R >512 R >512 R >512 R >512 R
Aztreonam >256 R 64 R >256 R >256 R ND ND ND ND
Cefoxitin 64 R >128 R >128 R >128 R 16 R 64 R
Ceftazidime >128 R >128 R >128 R >128 R 1 S 1 S
Chloramphenicol 64 R 64 R 64 R 64 R 512 R 512 R
Ciproﬂoxacin >256 R 64 R 256 R >256 R 2 R 2 R
Colistin 1 S 1 S 1 S 1 I 1 S 1 S
Ertapenem 1 S 64 R 64 R 64 R 0.25 S 1 I
Gentamicin 128 R 128 R 128 R 128 R 16 R 16 R
Imipenem 0.125 S 4 I 4 I 4 I 0.25 S 0.5 S
Meropenem 0.125 S 8 R 8 R 8 R 0.125 S 0.5 S
Piperacillin >512 R >512 R >512 R >512 R 128 R 128 R
Sulbactam >32 R >32 R >32 R >32 R 32 R >32 R
Tetracycline 16 R 8 R 16 R 16 R >256 R >256 R
Tigecycline 4 R 2 I 2 I 2 I 0.25 S 0.25 S
Tobramycin 64 R 64 R 64 R 128 R 16 R 16 R
MIC values are in mg/L.
S, sensitive; I, intermediate; R, resistant. ND, not determined.
TABLE 3. Ertapenem disk susceptibility testing in the presence/absence of clavulanic acid (Clav). Diameters are in millimetres
K1 K2 CTX-M-15 (1) CTX-M-15 (2) ATCC 13883 MGH78 578
Ertapenem 26 0 30 28 38 40
Ertapenem/Clav 31 12 37 36 38 40
Difference 5 12 7 8 0 0
FIG. 1. The pulsed-ﬁeld typing of K1 and K2 after digestion with
XbaI.
FIG. 2. A section of an SDS PAGE gel showing the major OMPs in
K1, K2, ATCC 13883, MGH78578, an MGH78578 meropenem
mutant and a K1 meropenem mutant. NB, nutrient broth; LB, Luria-
Bertani broth.
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explained by the mutations found in the ompK36 gene
sequence.
Mutation studies
Both K1 ertapenem and meropenem mutants were shown
to exhibit a similar resistance and identical OMP phenotype
to that of K2 (Table 2 and Fig. 2). MGH78578 meropenem
mutants exhibited porin loss similar to that of the K1
mutants and K2 strain, and showed an increase in MICs of
ertapenem from 0.25 to 1 mg/L. An increase from 0.25 to
0.5 mg/L was observed in the MIC of imipenem and an
increase from 0.125 to 0.5 mg/L was observed in the MIC of
meropenem. It is unlikely that porin loss alone can be
responsible for the carbapenem resistance exhibited by K2.
RT-PCR
RT-PCR analysis of K1, K2 and ATCC 13883 showed that
ramA and acrA were upregulated in both K1 and K2. This
suggests that much of the MDR phenotype exhibited by both
K1 and K2 may be attributed to active efﬂux mechanisms.
Analysis of the OMP gene expression showed that ompK35
was not expressed in either strain and ompK36 was
expressed at similar levels in each strain (Fig. 3). This sug-
gests that the OMP absent in both K1 and K2 was indeed
OmpK35 and that the absence of OmpK36 in K2 may be
due to a post-transcriptional process. It is likely that ompK35
expression is inhibited as a consequence of ramA overex-
pression, as has been found previously [26].
ramR sequencing
The sequencing of ramR, the repressor gene of ramA,
revealed that both K1 and K2 contained identical muta-
tions, which resulted in a premature stop codon at amino
acid position 83. RamA is a known regulator of the AcrAB
efﬂux pump; therefore the ramA and subsequent acrA over-
expression are likely to be attributable to this mutation
[27].
Transconjugation studies and plasmid proﬁling
K1/J62-2 transconjugants were obtained by selection with rif-
ampicin and gentamicin, but no transconjugants were
obtained with ceftazidime or meropenem. Susceptibility test-
ing showed that the transconjugants were resistant to genta-
micin and ceftazidime but not to carbapenems. PCR analysis
of the transconjugant strains showed that the transferred
plasmid contained CTX-M-15, TEM-1 and OXA-1 b-lacta-
mases. No K2/J62-2 transconjugants could be obtained. S1
nuclease plasmid proﬁling showed that K1 and K2 both con-
tained plasmids of c. 194, 97 and 70 kb, and K1 also
appeared to have an additional plasmid of <48 kb that was
not present in K2. Analysis of the transconjugant strains
showed that the plasmid of c. 97 kb had been transformed
into the recipient strain, indicating that CTX-M-15, TEM-1
and OXA-1 b-lactamase genes are present on the same plas-
mid. The ability to select for the transconjugants with genta-
micin indicates that the plasmid additionally carries an
aminoglycoside resistance determinant.
Discussion
Although the production of dedicated carbapenemases is
often viewed as the primary cause of carbapenem-resistant
K. pneumoniae infections, this study has shown that carbape-
nem resistance resulting in failed therapy is possible in the
absence of such enzymes. The importance of permeability
changes and the presence of b-lactamases, not normally
associated with carbapenem resistance, may have been
underestimated regarding their importance in conferring lev-
els of resistance that can be detrimental to infection treat-
ment. It has previously been suggested that CTX-M-15 may
be capable of contributing towards carbapenem resistance
through the hydrolysis of ertapenem, which this study sup-
ports [5]. The reduced ertapenem susceptibility levels
observed in strain K1 could be attributed to the presence of
the plasmid-borne b-lactamase, CTX-M-15. Although the
strain in question additionally contained other b-lactamase
genes (OXA-1, TEM-1, SHV-1), only the CTX-M-15 b-lac-
tamase has previously been reported to exhibit a degree
of carbapenemase activity and, in this case, it seems likely
that CTX-M-15 b-lactamase plays a contributory role in
exerting the carbapenem-resistant phenotype, speciﬁcally to
ertapenem.
FIG. 3. The expression of the selected genes in K1, K2 and ATCC
13883. NB, nutrient broth; LB, Luria-Bertani broth.
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The contribution of efﬂux mechanisms to carbapenem
resistance is currently a disputed topic, although efﬂux
undoubtedly plays an important role in conferring the MDR
phenotype displayed by the isolates in this study [11,28].
Although the precise effect of active efﬂux in exporting car-
bapenems from bacterial cells remains unknown, the upregu-
lation of the transcriptional activator ramA and subsequently
the RND family efﬂux pump gene, acrA, present in both
strains, may contribute to the high ertapenem MICs exhib-
ited. Resistance to ertapenem has been associated with a
combination of efﬂux mechanisms and permeability changes
in a study of clinical strains of E. cloacae [9]. It is possible
that ertapenem may be a suitable substrate for this efﬂux
system.
Expression of the major OMPs is certainly an important
factor for the access of various classes of antibiotics into the
bacterial cell and it appears that in K. pneumoniae, OmpK36
is of particular importance for carbapenem permeability. The
absence of this porin alone was shown to confer intermedi-
ate resistance to ertapenem and reduce susceptibility to
meropenem in the control strain MGH78578, and the
absence of this porin appears to be the sole factor in the
conversion of K1 into K2. These results suggest that
OmpK36 acts as the primary channel for the passage of er-
tapenem and meropenem but not for imipenem. It has been
shown that imipenem is capable of penetrating the bacterial
cell wall faster than meropenem [29], probably due to a
combination of its zwitterionic charge and smaller size, and
this may allow imipenem to penetrate other porins that me-
ropenem and ertapenem cannot.
No carbapenemases were found in either K. pneumoniae
strain despite being subjected to PCR detection using prim-
ers for all known carbapenemases found in Gram-negative
bacteria. This ﬁnding alongside the maintained imipenem sus-
ceptibility in K2 suggests that a carbapenemase is not
responsible for conferring the observed phenotype but
rather a combination of the aforementioned resistance
mechanisms. Perhaps the most important feature to note is
the ease by which porin-deﬁcient mutants could be selected,
particularly with ertapenem, which could inadvertently make
any subsequent therapy with meropenem less effective or
even defunct. Such ﬁndings are particularly worrying when
considering that, in the incidence of the spread of a similar
K. pneumoniae clone, such infections would be untreatable in
UK hospitals, where the only effective drugs, colistin and
imipenem, are not typically used.
This study demonstrates the interplay between different
resistance mechanisms that are capable of achieving levels of
carbapenem resistance, in the absence of a carbapenemase,
that are sufﬁcient to lead to therapy failure.
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